Rain Oncology's Phase 3 Data Casts Doubt On Other Trials: Analyst Reevaluate Their Views
Portfolio Pulse from Priya Nigam
Rain Oncology's Phase 3 MANTRA study of milademetan in dedifferentiated liposarcoma (DDLPS) failed to show statistically significant results, leading to a halt in studies for its lead candidate. Analysts have reevaluated their views on the company, with several downgrading their ratings and price targets.
May 23, 2023 | 3:19 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Rain Oncology's disappointing Phase 3 study results have led to halted studies and analysts downgrading their ratings and price targets on the stock.
The Phase 3 MANTRA study of milademetan in DDLPS failed to show statistically significant results, leading to a halt in studies for its lead candidate. This negative outcome has caused analysts to downgrade their ratings and price targets on Rain Oncology's stock, which will likely have a negative short-term impact on the stock price.
CONFIDENCE 100
IMPORTANCE 100
RELEVANCE 100